Orange Book product · Generic (ANDA)
DICLOFENAC POTASSIUM
DICLOFENAC POTASSIUM
At a glance
Oct 19, 2021
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Oct 19, 2021
4 yr 9 mo ago
Today
Pharmaceutical detail
Active ingredient
DICLOFENAC POTASSIUM
Strength
25MG
Dosage form
CAPSULE
Route
ORAL
TE code
AB
Application
ANDA 213875
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of DICLOFENAC POTASSIUM
- 2009CAMBIABrand (NDA)
NDA 022165 · ASSERTIO SPECLTY
- 2009ZIPSORBrand (NDA)
NDA 022202 · ASSERTIO SPECLTY
- 1993CATAFLAMBrand (NDA)
NDA 020142 · NOVARTIS
- 2025DICLOFENAC POTASSIUMGeneric (ANDA)
ANDA 217010 · UMEDICA
- 2025DICLOFENAC POTASSIUMGeneric (ANDA)
ANDA 215750 · UMEDICA
- 2025DICLOFENAC POTASSIUMGeneric (ANDA)
ANDA 215891 · TORRENT
- 2024DICLOFENAC POTASSIUMGeneric (ANDA)
ANDA 218011 · TARO
- 2023DICLOFENAC POTASSIUMGeneric (ANDA)
ANDA 215787 · SENORES PHARMS
- 2022DICLOFENAC POTASSIUMGeneric (ANDA)
ANDA 216635 · ALKEM LABS LTD
- 2022DICLOFENAC POTASSIUMGeneric (ANDA)
ANDA 215375 · ANNORA PHARMA
- 2021DICLOFENAC POTASSIUMGeneric (ANDA)
ANDA 215585 · INGENUS PHARMS LLC
- 2021DICLOFENAC POTASSIUMGeneric (ANDA)
ANDA 075229 · RUBICON RESEARCH
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
